Surgical Site InfectionPURPOSENCT04057092
Perioperative Immunonutrition in Patients Undergoing Gynecologic or General Elective Surgery (PURPOSE)
A study testing Dietary Supplement INergy-FLD in people with Surgical Site Infection and Post-Op Complication, run by Hamilton Health Sciences Corporation at 1 site in Canada.
Trial summary
The objective of the implementation pilot is to assess the practicality of introducing a perioperative immunonutrition protocol into a hospital environment as well as a true measure of impact on the rate of surgical site infection (SSI). Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Surgical Site Infection, Post-Op Complication
- What is being tested?
- Dietary Supplement INergy-FLD
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 72 participants
- Where
- 1 siteCanada
- Study dates
- 1 Aug 2018to 31 Dec 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Men and women 18 years of age or older who are undergoing gynecologic oncology or general surgery (including resectable types of cancer) for which an elective operation is planned.
- Patients who are lactose intolerant are eligible for the study because the amount of lactose in INergy-FLD® is minimal (trace).
Who cannot join
- Cannot tolerate enteral intake
- Organ failure (liver, kidney)
- Patients currently on steroids
- Female patients who are pregnant and/or lactating
- Galactosemia
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Perioperative Immunonutrition in Patients Undergoing Gynecologic or General Elective Surgery (PURPOSE): a Feasibility Trial
The objective of the implementation pilot is to assess the practicality of introducing a perioperative immunonutrition protocol into a hospital environment as well as a true measure of impact on the rate of surgical site infection (SSI).
Read the detailed description
Postoperative infectious complications are independently associated with increased hospital length of stay (LOS) and cost, and contribute to significant inpatient morbidity. Despite recent advances in surgical techniques and perioperative management, the rate of postoperative infectious complications remains high with 54% of all hospital-acquired-infections occurring in high-risk surgical populations.2 Poor nutritional status along with surgical stress predisposes patients to postoperative complications and immune depression. Research is now demonstrating the importance of additional perioperative nutritional support through the use of enteral and parenteral feeds in high-risk patients, with a specific focus on the role of immunonutrition. Immunonutrition substrates have been found to modulate postsurgical immuno-depression and inflammatory responses and positively impact patient outcomes.
Immunonutrition is defined as a solution that contains nutrients such as arginine, omega fatty acids, and protein. Arginine deficiency after surgical stress was first reported over 30 years ago, and recent studies have demonstrated that the perioperative use of arginine-supplemented diets have the ability to decrease the rate of postoperative infection. Arginine is an amino acid that is synthesized in the body but not in high enough concentration to support metabolic needs during periods of stress, such as surgery. While under stress, arginine is the primary fuel source for T-cells and helps maintain immune function and decrease the risk of infection. Th1 induced macrophages also use arginine for many of their immune functions. In addition, omega fatty acids, such as n-6 and n-3, are derived from fish oil and have been shown to attenuate the production of inflammatory compounds and ultimately reduce the cytotoxicity of inflammatory cells. This role that omega fatty acids play in the resolution of inflammation results in enhanced wound healing and improved lymphocyte function. Finally, whey protein substrates have great potential to be used effectively to support post-surgery anabolism. Whey proteins are of high quality, have proved to be effective in modulating muscle protein synthesis, and are a convenient way to supplement protein needs in malnourished patients. Whey proteins also have immuno-modulating properties, including biosynthesis of antioxidant glutathione, which could attenuate the catabolic effects of surgery and spare protein. These ingredients have been shown to work synergistically and are associated with significantly better overall and recurrence-free survival. Each element works towards improving the immune response through modulation of excessive inflammatory responses and replenishing depleted nutrients when the body is in a state of surgical stress.13
The HHS implementation pilot will provide preoperative patients with EMN's immunonutrition formula, INergy-FLD®. INergy-FLD® is an immune-modulating solution that contains whey protein isolate, refined fish oil with omega 6 fatty acids, antioxidants such as vitamins A, C, D and E, and has an elevated amino acid concentration with 4.2 grams of L-Arginine per serving. It has a natural citrus flavor, low sugar and a trace of lactose, and therefore can be tolerated by patients who are lactose intolerant. INergy-FLD® is categorized under Health Canada as a formulated liquid diet (FLD). INergy-FLD® complies with the detailed and explicit compositional and labeling requirements of an FLD supplement as well as providing complete directions for preparation and the use of the food product (Food Category: CFIA)
Patient reported consumption diaries will be used to track the consumption of INergy-FLD® by patients in the perioperative period, and patient feedback will be sought on experience and barriers in implementation of this regimen. In order to track the impact of INergy-FLD® on the rate of postoperative infectious complications, HHS will rely on the NSQIP patient-outcome audit system. According to two new studies presented by researchers from the American College of Surgeons (ACS), NSQIP provides more accurate data than administrative data for driving surgical quality improvement. NSQIP codes are standardized, very specific, and can identify the primary reason for readmission. Other advantages of NSQIP include the detail of preoperative risk variables collected by the database, allowing for a more robust risk-adjusted analysis. Using this database available at HHS, EMN will be able to accurately analyze the impact of INergy-FLD® immunonutrition on surgical patient outcomes.
- Conditions
- Surgical Site Infection, Post-Op Complication
- Being tested
- Dietary Supplement INergy-FLD
- Keywords
- perioperative immunonutrition, clinical nutrition, infection prevention
- Medical subject headings
- Surgical Wound Infection, Postoperative Complications
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dietary Supplement INergy-FLDDietary supplement
Also called INergy-FLD®
INergy-FLD® is an immune modulating formula containing various ingredients including L-Arginine, whey protein isolate, and omega-6 fatty acid, aimed to attenuate excessive inflammatory responses without being immunosuppressive and to replenish nutrients that are depleted in a state of surgical stress, thereby enhancing the recovery process and decreasing the risk of infection. The volume of the beverage is 250mL per serving and patients will be asked to consume 3 servings periodically per day for 5 days prior to surgery and 5 days following surgery.
| Study group | Role | What they receive |
|---|---|---|
| Intervention group | Experimental | Eligible patients undergoing gynecologic oncology or general surgery will receive perioperative immunonutrition supplement INergy-FLD®. The operation should occur within 8 weeks from enrolment in the pilot study. Upon assessment and enrolment in the pilot study, patients will have a consultation with their physician in the preoperative clinic and will be provided with 10 days worth of INergy-FLD® beverages, 30 servings total. Receives: Dietary Supplement: Dietary Supplement INergy-FLD |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of compliance to protocol
a visual assessment of empty nutrition packages, to ensure patient has consumed 70% or more of the nutrition supplements
Measured: 5 days postoperative
Secondary outcomes (2)
Surgery site infection (SSI)
SSI's will be determined and tracked by NSQIP following the patients' hospital stay and up to 30 days from the initial operation including superficial, fascia, and deep infections. The NSQIP is not a measure, but rather a program by which hospitals report surgical outcomes including infections. The outcome of importance will be the number of surgery site infections reported by each group
Measured: 30 days postoperative
Length of hospital stay
Number of days hospital stay post-surgery
Measured: up to 12 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Aug 2019
- Study start1 Aug 2018
- Primary completion30 Sep 2020
- Study completion31 Dec 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Surgical Site InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Eligible and consenting gynecologic oncology and general surgery patients will receive EMN's nutritional supplement INergy-FLD® both before and after elective surgery.
- Masking
- None (open label)
- Enrolment
- 72 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hamilton Health Sciences Corporation
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Limor Helpman, Hamilton Health Sciences Corporation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04057092
- Sponsor's protocol ID
- 2018-4462
- Acronym
- PURPOSE
- Status last verified
- May 2021
- First submitted
- 12 Aug 2019
- Last updated
- 25 May 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Perioperative Immunonutrition in Patients Undergoing Gynecologic or General Elective Surgery (PURPOSE): a Feasibility Trial
- ClinicalTrials.gov ID
- NCT04057092
- Acronym / sponsor ID
- PURPOSE / 2018-4462
- Conditions
- Surgical Site Infection, Post-Op Complication
- Keywords
- perioperative immunonutrition, clinical nutrition, infection prevention
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 72 participants (actual)
- Lead sponsor
- Hamilton Health Sciences CorporationUniversity, hospital or other
- Study start
- 1 Aug 2018 (actual)
- Primary completion
- 30 Sep 2020 (actual)
- Study completion
- 31 Dec 2020 (actual)
- First posted
- 15 Aug 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the implementation pilot is to assess the practicality of introducing a perioperative immunonutrition protocol into a hospital environment as well as a true measure of impact on the rate of surgical site infection (SSI).
Detailed description
Postoperative infectious complications are independently associated with increased hospital length of stay (LOS) and cost, and contribute to significant inpatient morbidity. Despite recent advances in surgical techniques and perioperative management, the rate of postoperative infectious complications remains high with 54% of all hospital-acquired-infections occurring in high-risk surgical populations.2 Poor nutritional status along with surgical stress predisposes patients to postoperative complications and immune depression. Research is now demonstrating the importance of additional perioperative nutritional support through the use of enteral and parenteral feeds in high-risk patients, with a specific focus on the role of immunonutrition. Immunonutrition substrates have been found to modulate postsurgical immuno-depression and inflammatory responses and positively impact patient outcomes.
Immunonutrition is defined as a solution that contains nutrients such as arginine, omega fatty acids, and protein. Arginine deficiency after surgical stress was first reported over 30 years ago, and recent studies have demonstrated that the perioperative use of arginine-supplemented diets have the ability to decrease the rate of postoperative infection. Arginine is an amino acid that is synthesized in the body but not in high enough concentration to support metabolic needs during periods of stress, such as surgery. While under stress, arginine is the primary fuel source for T-cells and helps maintain immune function and decrease the risk of infection. Th1 induced macrophages also use arginine for many of their immune functions. In addition, omega fatty acids, such as n-6 and n-3, are derived from fish oil and have been shown to attenuate the production of inflammatory compounds and ultimately reduce the cytotoxicity of inflammatory cells. This role that omega fatty acids play in the resolution of inflammation results in enhanced wound healing and improved lymphocyte function. Finally, whey protein substrates have great potential to be used effectively to support post-surgery anabolism. Whey proteins are of high quality, have proved to be effective in modulating muscle protein synthesis, and are a convenient way to supplement protein needs in malnourished patients. Whey proteins also have immuno-modulating properties, including biosynthesis of antioxidant glutathione, which could attenuate the catabolic effects of surgery and spare protein. These ingredients have been shown to work synergistically and are associated with significantly better overall and recurrence-free survival. Each element works towards improving the immune response through modulation of excessive inflammatory responses and replenishing depleted nutrients when the body is in a state of surgical stress.13
The HHS implementation pilot will provide preoperative patients with EMN's immunonutrition formula, INergy-FLD®. INergy-FLD® is an immune-modulating solution that contains whey protein isolate, refined fish oil with omega 6 fatty acids, antioxidants such as vitamins A, C, D and E, and has an elevated amino acid concentration with 4.2 grams of L-Arginine per serving. It has a natural citrus flavor, low sugar and a trace of lactose, and therefore can be tolerated by patients who are lactose intolerant. INergy-FLD® is categorized under Health Canada as a formulated liquid diet (FLD). INergy-FLD® complies with the detailed and explicit compositional and labeling requirements of an FLD supplement as well as providing complete directions for preparation and the use of the food product (Food Category: CFIA)
Patient reported consumption diaries will be used to track the consumption of INergy-FLD® by patients in the perioperative period, and patient feedback will be sought on experience and barriers in implementation of this regimen. In order to track the impact of INergy-FLD® on the rate of postoperative infectious complications, HHS will rely on the NSQIP patient-outcome audit system. According to two new studies presented by researchers from the American College of Surgeons (ACS), NSQIP provides more accurate data than administrative data for driving surgical quality improvement. NSQIP codes are standardized, very specific, and can identify the primary reason for readmission. Other advantages of NSQIP include the detail of preoperative risk variables collected by the database, allowing for a more robust risk-adjusted analysis. Using this database available at HHS, EMN will be able to accurately analyze the impact of INergy-FLD® immunonutrition on surgical patient outcomes.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Eligible and consenting gynecologic oncology and general surgery patients will receive EMN's nutritional supplement INergy-FLD® both before and after elective surgery.
| Arm | Type | Receives |
|---|---|---|
| Intervention group | Experimental | Dietary Supplement: Dietary Supplement INergy-FLDEligible patients undergoing gynecologic oncology or general surgery will receive perioperative immunonutrition supplement INergy-FLD®. The operation should occur within 8 weeks from enrolment in the pilot study. Upon assessment and enrolment in the pilot study, patients will have a consultation with their physician in the preoperative clinic and will be provided with 10 days worth of INergy-FLD® beverages, 30 servings total. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Men and women 18 years of age or older who are undergoing gynecologic oncology or general surgery (including resectable types of cancer) for which an elective operation is planned.
- Patients who are lactose intolerant are eligible for the study because the amount of lactose in INergy-FLD® is minimal (trace).
Key exclusion criteria (5 listed)
- Cannot tolerate enteral intake
- Organ failure (liver, kidney)
- Patients currently on steroids
- Female patients who are pregnant and/or lactating
- Galactosemia
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dietary Supplement INergy-FLDAlso: INergy-FLD®INergy-FLD® is an immune modulating formula containing various ingredients including L-Arginine, whey protein isolate, and omega-6 fatty acid, aimed to attenuate excessive inflammatory responses without being immunosuppressive and to replenish nutrients that are depleted in a state of surgical stress, thereby enhancing the recovery process and decreasing the risk of infection. The volume of the beverage is 250mL per serving and patients will be asked to consume 3 servings periodically per day for 5 days prior to surgery and 5 days following surgery. | Dietary supplement | Intervention group |
Primary outcome
Rate of compliance to protocol
Time frame: 5 days postoperative
a visual assessment of empty nutrition packages, to ensure patient has consumed 70% or more of the nutrition supplements
2 secondary outcomes
Surgery site infection (SSI)
Time frame: 30 days postoperative
Length of hospital stay
Time frame: up to 12 weeks.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 May 2021.
- Individual participant dataSharing planned: No
Related trials for Surgical Site Infection
Not yet recruitingObservational study
Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)
Abdominal Aortic Aneurysm, Morbid Obesity
RecruitingPhase 2
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
Head and Neck Cancer, Head and Neck Squamous Cell Cancer
Recruiting
Safety and Efficacy of NTP in Thyroid Surgery: Pilot Study on Morbidity Prevention and Adjuvant Oncological Control
Thyroid Diseases, Wound Healing
RecruitingObservational study
Novosyn® CHD vs Polyglactin 910 Suture to Close Wounds After Emergency or Elective Laparotomy or Laparoscopic Surgery
Surgical Site Infection
Not yet recruiting
Safety Assessment of Placing a Single Dental Implant Without Antibiotic Prophylaxis in Simple Cases: A Pilot Study
Tooth Loss and Rehabillitation, Dental Implant Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dietary Supplement INergy-FLD in people with Surgical Site Infection and Post-Op Complication, run by Hamilton Health Sciences Corporation at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of compliance to protocol (time frame: 5 days postoperative). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 May 2021.